By Jeremy Murphree, patient advocate, Morgellons Survey
How many other people have Morgellons? We don’t have a reliable U.S. count. In one Northern California health plan, researchers found about four people per 100,000 members who reported material coming from their skin along with a sore, a rash, or an uncomfortable sensation. A Lyme specialty practice asked a different question. How many of its patients had tiny fibers an examiner could see in a skin lesion or under unbroken skin? Neither study tells us how many Americans develop Morgellons each year. (1, 2)
Imagine this visit. A patient describes a painful sore with a strand coming out of it. She sees the strand on Monday. By her Friday appointment, the sore has healed. The examiner sees no fiber.
Pearson · Northern California health plan
The team asked about material emerging from the skin together with a lesion or a disturbing skin sensation.
Her report could meet the symptom rule.
Fesler · Lyme specialty practice
The team looked for microscopic fibers in a lesion or beneath unbroken skin.
This visit does not document the fiber finding.
What is Morgellons?
A reader who asks “Would they have counted me?” needs both pieces of information: who was eligible for the study and what finding qualified. Pearson studied members of a health plan. Fesler studied patients who had already tested positive for Lyme disease at a specialty practice. (1, 2, 3)
I once wrote that the “incidence” of Morgellons was roughly 6% of Lyme patients. I used the wrong word. Some of the clinic patients had been living with skin findings for months when they were examined. Counting them tells us about people who reached that clinic. It doesn’t tell us how many people got sick that year. (2, 4)
What about the fibers themselves?
Whether Morgellons is a distinct skin disease is a separate question from how a study counted patients. Middelveen and colleagues reported keratin or collagen in filaments from selected tissue specimens. Pearson’s team found that much of the material it analyzed was consistent with cotton. Only subsets of Pearson’s participants underwent examinations or specimen testing. The laboratory results describe those specimens. They cannot tell us what every person who entered either study had in their skin. (1, 5)
How many people have Morgellons?
We don’t know how many people in the United States have Morgellons today. One study gives us a local estimate. From July 2006 through June 2008, Pearson and colleagues looked for cases among Kaiser Permanente members in Northern California. Members met the study definition if they reported fibers or other material coming from their skin along with a sore, rash or other skin lesion, or a troubling sensation such as stinging.
104 members
Found through medical records. The team used this group to calculate prevalence.
11 members
Contacted the researchers themselves. They counted toward the study total only.
The team compared the 104 cases with average membership at the facilities whose records it could search. That worked out to 3.65 cases per 100,000 members over the study period.
In round numbers, the researchers found about four cases for every 100,000 health-plan members. Someone whose symptoms never appeared in a searchable clinic record could be missed. The study also left open how common Morgellons would be if every case required a clinician to see a filament. (1)
You may see this number elsewhere. DermNet says, “Prevalence is approximately 3.65 per 100,000 individuals.” Its page classifies Morgellons as a subtype of delusional infestation. The California researchers counted people on the basis of the skin symptoms and material they reported. A diagnosis of delusional infestation was never an entry requirement. (6)
Technical note
The study ran from July 2006 through June 2008. Eligible participants were English-speaking Kaiser Permanente Northern California members aged 13 or older. The researchers counted health-plan members who reported material coming from their skin along with a sore, rash, or troubling skin sensation. For example, someone whose sore healed before the appointment could still count based on what they reported. If the study had required a clinician to see a fiber in the skin, that same person’s report alone would no longer qualify.
Using the original rule, the researchers estimated 3.65 cases per 100,000 members at the facilities they studied. They gave a range of 2.98 to 4.40 per 100,000 to show the uncertainty around that estimate (the 95% confidence interval). Finding out how common examiner-confirmed fibers are, or how common these symptoms are nationwide, would require a separate count. (1)
How many people develop Morgellons each year?
We do not know. The published studies reviewed here do not measure first onset of Morgellons in a defined population over a known amount of time at risk. (1)
Imagine a woman who walks into a clinic today with a sore that first opened three years ago. Under the study’s definition, she might count among the people who have the condition today. That is the idea behind prevalence. If we are counting people who developed it this year, the date she reached the clinic cannot move the beginning of her illness forward three years. That is the distinction incidence depends on.
A health system could count first visits or first diagnoses even when it cannot establish symptom onset. Those figures would tell us something valuable about demand for care and time to recognition. Calling them new illnesses would hide precisely the delay many patients want researchers to understand. A Minnesota study did measure first diagnoses of delusional infestation. Its criteria addressed a different clinical question and did not require an examiner-observed filament. Its incidence rate therefore cannot fill the gap for filament-defined Morgellons. (7)
Where does “6% of Lyme patients” come from?
| Who was seen? | What was counted? | What remains unknown? |
|---|---|---|
| 500 patients at an Australian clinic (8) | 29 had a Morgellons finding recorded by skin microscopy (5.8%). | How many of the 500 had microscopy, and how many of the 29 belonged to the Lyme-positive group? |
| 1,000 patients with positive Lyme blood tests at a North American specialty practice (2) | 62 met the skin criteria (6.2%). After two follow-up exclusions, 60 entered the analysis (6.0%). | Would the same proportion be found in primary care? How many patients first developed the finding that year? |
In their 2018 paper, Fesler and colleagues used the clinic figure a second way. They multiplied 6% by an earlier estimate of 329,000 U.S. Lyme diagnoses per year and proposed at least 19,740 annual Morgellons cases. In the same sentence, the authors called the clinic’s 6% prevalence and the projected 19,740 incidence. The clinic records tell us how many patients had the skin finding when examined. To measure annual incidence, researchers would need to establish how many people first developed it during that year. (2)
In an October 2026 podcast interview, Fesler used the same calculation her team had published in 2018. This time she started with roughly 500,000 U.S. Lyme diagnoses per year. Six percent of that larger number gives the 30,000 new Morgellons cases a year discussed in the interview. You can hear the clinic discussion at 4:31–5:17 and the national calculation at 21:50–22:16. Both projections assume that the clinic’s percentage applies nationwide and that the Morgellons findings began in the year of the Lyme diagnosis. The study did not establish either point. (9, 2, 10)
How the 6% figure traveled from one source to the next
2015. Mayne’s Table 2 recorded 29 findings among all 500 clinic patients. Its column heading used the word incidence. The table gives no separate percentage for people with a Lyme diagnosis. (8)
2016. A review described Mayne’s result as a percentage of Lyme patients. (11)
April 2018. Fesler’s introduction described Mayne’s patients as having positive Lyme blood tests. That was a requirement for Fesler’s own clinic group. Her team then applied its 6% to 329,000 annual U.S. Lyme diagnoses and proposed at least 19,740 Morgellons cases per year. This is where the clinic percentage became a national annual projection. (2)
May 2018. A foundation press release presented 6% as an established share of Lyme patients while announcing a separate culture study. (12, 13)
2019–2026. A 2019 skin-specimen paper repeated the percentage. My 2023 photography article used the word incidence. In 2026, Undark attributed the estimate to proponents. Each is an example of how the claim was repeated. The clinic counts still come from the two studies above. (14, 4, 15)
A consumer page illustrates how easily the figure can travel the other way. Mya Care describes roughly six percent of Morgellons patients as testing positive for ongoing infections and tickborne Lyme disease. Start with 100 people with Lyme and ask how many have a skin finding. Now start with 100 people with the skin finding and ask how many have Lyme. You need different patient lists to answer those questions. Switching the words on either side of with changes what the percentage means. (16)
How long had patients had these findings?
Of the 60 patients analyzed by Fesler, 47 (78%) met the authors’ “late disseminated” Morgellons category at presentation. The category described lesions or fibers present for more than six months and affecting more than one body area. A first visit can occur long after the first skin finding. (2, 17)
Is “half a million Lyme cases a year” the right starting number?
Do half a million Americans get Lyme disease each year? We don’t know. From 2010 through 2018, researchers estimated that doctors diagnosed and treated about 476,000 people for Lyme disease each year. During those same years, about 35,000 cases a year reached public health officials. Some people who had Lyme were never reported, and some people treated for suspected Lyme had another illness. (10) A separate study of blood tests estimated that about 288,000 of the people tested in 2008 had been infected. Some positive tests could reflect an older infection, and the study missed people who were never tested. Hundreds of thousands of new infections in a year is plausible, but the actual annual number is still unknown. (18)
CDC said a new rule allowing areas where Lyme is common to count cases from lab results alone likely explains why the U.S. reported total rose from an average of 37,118 a year in 2017–2019 to 62,551 in 2022. (33)
For Morgellons, the question is whether the 476,000 people represented by that estimate resemble the patients in Fesler’s Lyme specialty practice closely enough to use its 6% figure. The two studies counted people in different ways. (2, 10)
Kiersten Kugeler and colleagues used commercial insurance records to estimate how often Americans received a Lyme diagnosis and treatment. For outpatient visits, they looked for a Lyme billing code paired with an antibiotic prescription of about a week or longer. A clinician may reasonably begin treatment on suspicion. Some infections escape surveillance, and some people treated presumptively have another illness. The authors explicitly said they could not untangle those contributions to the gap between their estimate and routine reporting. Fesler’s patients had positive Lyme serology and reached a specialist. Kugeler counted clinical decisions across a far broader population, with no required test result. (10)
Technical note
The annual average for 2010–2018 was approximately 476,000, with a 95% credible interval of 405,000–547,000. Outpatient identification required a Lyme code and a linked prescription for an appropriate antibiotic. The journal’s plain-text version gives >7 days. The printed article (p. 616) and the companion methods paper by Schwartz et al. both specify ≥7 days. (10, 19) Inpatient identification used diagnosis-code rules. Adjustments addressed the national population, adults aged 65 and older, and omitted Lyme codes. Surveillance recorded about 35,000 cases annually in that period. Low-incidence states accounted for 19% of claims diagnoses versus about 5% in surveillance, a difference the authors said overdiagnosis could help explain. (10)
What happened when researchers checked Lyme billing records against patient charts?
In Massachusetts, researchers reviewed 128 records flagged by a Lyme billing code and an antibiotic prescription. They classified 85 as confirmed or probable Lyme cases (66.4%). Including 35 suspected cases brought the count to 120 (93.8%). (20) In a later study, researchers reviewed 107 records flagged by a similar rule in Wisconsin and another 107 in states neighboring high-incidence areas. The share that met confirmed or probable Lyme criteria was 76.6% in the Wisconsin group and 28.0% in the second group. (21) These differences show how much the location and the definition of a case matter. A chart that falls short of the Lyme criteria does not, by itself, identify another diagnosis.
Researchers estimated that 476,000 people a year were diagnosed and treated for Lyme disease in 2010–2018. Uncheck a box to see what each adjustment adds. (10)
The insurance records covered people under 65. About 1 in 5 Lyme cases reported to health departments involved someone 65 or older. Researchers used that share to include the older adults the records missed.
Only 43 in 100 records that met the study’s Lyme criteria carried the Lyme billing code. Allowing for the missing codes more than doubled the estimate.
Estimated U.S. Lyme diagnoses and treatments per year, 2010–2018, with these choices: 476,000
How the estimate was calculated
The researchers first adjusted the insurance data by state and five-year age group using 2015 U.S. Census population estimates. The middle box of their flowchart shows the result for the states included in the analysis. It gives an estimated 1,000,596 coded Lyme diagnoses among people under 65 over nine years. The lowest box on the right shows that those states accounted for 67.6% of Lyme cases reported to CDC. See the figure on page 617, the second page of the PDF. (10)
Dividing 1,000,596 by nine gives a yearly average for the included states. Dividing that average by 0.676 gives our nationwide estimate of about 164,000 people under 65 coded and treated per year. People under 65 made up 80.3% of reported cases. Using that share to include older adults brought the researchers’ estimate to 205,000 across all ages. Their final adjustment, for missing Lyme billing codes, brought it to 476,000 per year (95% credible interval, 405,000–547,000). (10)
The state options are hypothetical. A single state shows what the estimate would be if that state’s coding pattern applied nationwide.
Why syphilis matters to the Lyme and Morgellons counts
In their 2020 paper, Marianne Middelveen, Melissa Fesler, Raphael Stricker and colleagues wrote that when Morgellons symptoms are present, “for most patients the stage of disease progression is comparable to that of secondary syphilis.” They explained that sores containing fibers can appear long after other symptoms have begun. The authors also saw a resemblance in the range of skin changes, including raised bumps and open sores. They treated the fibers as a separate feature. Their proposed definition of Morgellons required colored fibers embedded in or sticking out of the skin. (32)
What did the syphilis testing show? The researchers used a DNA test called PCR to look for Treponema pallidum, the bacterium that causes syphilis, in samples from 14 of the 16 participants. All 14 results were negative. The methods describe testing material from lab cultures, but the paper does not identify the original specimen for each of those 14 results or report syphilis blood antibody results for the participants. (32) Clinicians usually use two kinds of blood antibody tests to diagnose syphilis. How well PCR detects the bacterium depends partly on what was sampled, so these negative results alone cannot rule out syphilis. (30)
Why does that resemblance matter when counting cases? If a study enrolls people because of how a sore looks, its readers need to know how the researchers checked for other possible causes. A first Lyme blood test alone cannot settle the question, because antibodies from syphilis can also react on some Lyme screening tests. CDC recommends a second test when the first result is positive or unclear. The chart below shows what happened when researchers applied both steps to samples from people known to have syphilis. (22, 23)
Researchers tested blood samples from 20 people who had active syphilis. Their first Lyme test was the VIDAS whole-cell sonicate enzyme immunoassay (WCS EIA), a screening test that looks for antibodies that react with material from Lyme bacteria. These samples cannot tell us how many people counted in U.S. Lyme estimates had syphilis. Each square below represents one sample. Shaded squares show how many tested positive at the selected step. (23)
17 of 20 reacted on the VIDAS screening test (85%).
Why the second tier matters. Seventeen samples reacted on the screening test. When the researchers applied the follow-up test and the study’s rule for how long someone had been ill, only one sample met the criteria for a positive Lyme result. These results cannot be used to adjust the national Lyme estimate.
Studies of people with syphilis found that some samples reacted on Lyme screening tests. To estimate misclassification in U.S. Lyme figures, researchers would need to start with the people counted as having Lyme and check their diagnoses. The studies reviewed here do not give that percentage. (24, 23, 25)
What if the tests are reversed? Patriquin and colleagues found evidence that syphilis antibodies can react on a Lyme screen. Their study found no evidence that previous Lyme infection caused false positives on the syphilis screen they evaluated. An unexpected reactive syphilis screen still calls for the recommended follow-up tests. Neither direction of testing supplies a percentage to subtract from the U.S. Lyme estimate. (29, 30)
How often does Morgellons appear in delusional infestation studies?
Calling your condition Morgellons, mentioning fibers during a visit, and meeting an examiner’s criteria for Morgellons are three different ways someone might enter a count. Two referral studies show why that matters. (26, 27)
Each dot is one person in that study. A filled dot means the person gave the answer shown.
Connecticut entomology referrals (26)
Who called their condition Morgellons?
7 of 264 (2.7%)
Seven people used the name Morgellons among those referred with suspected delusional infestation.
Mayo Clinic (27)
Who mentioned fibers?
29 of 143 (20.3%)
These patients had a diagnosis of delusional infestation and a recorded description. Some mentioned more than one material.
A patient can mention fibers without using the name Morgellons. Neither count tells us how many people had fibers documented in a sore.
DermNet estimates that about one in four people with delusional infestation have what it calls Morgellons. The page lists a bibliography but gives no patient count alongside that estimate. (6) A psychiatry review uses similar wording for a different observation. It says that up to one in four describe an infestation with nonliving material, such as fibers. That tells us what people described. To find out how many had fibers emerging from a sore, researchers would need to examine their skin. (31)
Pearson and colleagues estimated 3.65 cases per 100,000 Northern California health-plan enrollees using a patient-reported skin presentation. An Olmsted County study estimated a point prevalence of 27.3 per 100,000 for delusional infestation overall. Those studies used different populations, time frames and case definitions. Dividing the two estimates would give a ratio with no shared denominator. (1, 28)
Imagine researchers examine the same people for both conditions. They could then answer two questions by changing which group they start with.
Start with people diagnosed with delusional infestation.
How many also meet the study’s Morgellons skin criteria?
Start with people who meet the study’s Morgellons skin criteria.
How many also meet the criteria for delusional infestation?
I found no population-based study that assessed the same people using both sets of criteria. Both percentages remain unknown.
What would it take to actually count Morgellons?
Follow people in several defined communities, agree in advance on what qualifies as a case, and record when the finding first appears. Give people a way to take part through primary care, dermatology or outreach whether or not they have ever been tested for Lyme.
I would keep two counts side by side. One would preserve the patient-reported experience, including people whose lesions heal before an appointment. The other would require a documented finding at a particular skin site. Publish how often the groups overlap. For each person, record when the lesion was first noticed, when it was photographed and when a clinician first saw it. When onset is uncertain, report a first documented finding. Keep a separate record of recurrences so that someone with six painful episodes counts once as a newly affected person and six times in a study of episodes.
Give independent reviewers images of suspected Morgellons, other crusted or ulcerated skin conditions, and unaffected skin taken using the same methods. Keep the proposed diagnosis and Lyme status hidden from reviewers. Can they agree on where the material lies? How often do they see the same feature in the comparison images? Agreement would show that observers can recognize a feature consistently. The comparisons would tell us whether recognizing it helps distinguish the groups.
Technical note
Report uncertainty, missed examinations and losses to follow-up. To test the Lyme hypothesis, follow people with and without Lyme from the same communities using the same baseline skin examination and follow-up schedule. Publish both rates before attempting a national extrapolation.
- 1. Define a caseWho counts, and what qualifies?
- 2. Document new findingsRecord onset, photos, and exams.
- 3. Calculate the rateFirst onsets ÷ person-time at risk
The rule for this example. Count someone once if their first qualifying sore appears during follow-up. An examiner must see a fiber embedded in or emerging from the sore under magnification, photograph it in place, and have a second reviewer confirm the finding. Everyone receives the same examination. A psychiatric diagnosis is recorded separately. Here, “included” and “excluded” refer to the new-case count. Everyone’s visit remains part of the study record.
Leah · Included
Leah, 46, has had a fixed belief for two years that mites are breeding under her skin. After examining her skin and specimens and assessing other possible causes, her clinical team diagnosed delusional infestation. Her first study exam showed no qualifying sore. Six weeks later, she develops her first such sores on her forearm. Two reviewers see and photograph fibers emerging from the edges.
Why? The new sores meet the skin rule. The photographs document where the fibers emerge. They do not establish that mites caused them.
Martin · Excluded
Martin, 53, also has a documented diagnosis of delusional infestation after a medical and psychiatric assessment. He remains convinced that mites are breeding under his skin. He phones the study team when two painful sores appear. At that visit and a repeat exam while the sores are still open, the reviewers see crusts and no emerging or embedded fibers.
Why? His sores and pain are recorded. Neither exam documents the fiber finding required for the new-case count.
Maya · Included
Maya, 34, had a clear skin exam when she joined. In June she notices her first forearm sore and calls while it is still open. An examiner photographs a fine strand emerging at the margin under magnification. A second reviewer confirms it at the same spot in the image.
Why? Her first qualifying sore appeared during follow-up. One sore is enough to count her once.
Sam · Excluded
Sam, 62, brings a dated dermatology photograph from three months before enrollment. It shows a fiber emerging from a shin sore. The study team sees the same finding at his first visit and again when a new sore opens in July.
Why? Sam meets the skin definition and belongs in the count of existing cases. The July sore is a recurrence, so he is excluded from the count of newly affected people.
Jordan · Included
Jordan, 40, reported no earlier episodes and had no qualifying sore at enrollment. The team documents fibers emerging from his first ankle sore in April. The sore heals. Two more sores with the same finding appear over the summer.
Why? April is his first qualifying episode. The study counts one newly affected person and records the later episodes separately.
Elena · Excluded
Elena, 57, notices a strand at the edge of a cheek sore between visits. By the time she can get to the clinic, the sore has healed. She brings the strand in an envelope. There is no photograph showing it in place.
Why? The team records her account. A loose strand cannot show where it lay before the sore healed. This episode stays in the patient-reported group, and she can return if another sore appears.
Three of these six fictional patients enter the new-case count. Leah and Martin have the same psychiatric diagnosis. Leah has a newly documented sore with fibers emerging from it. Martin’s exam shows sores without that finding. Sam also has a documented fiber, but his dates answer a different question: he already had the finding when the study began.
A made-up example of a one-year count. Suppose researchers follow 1,000 people for a year. None has ever had a sore that meets the study’s rule. Two people develop their first such sore during the year. One of them has three more sores that summer, but the researchers still count that person only once. In this made-up example, 2 of 1,000 people developed their first qualifying sore that year.
Questions to ask any source
Ask what was observed and whether the wording preserves the limits of that observation. These questions apply to foundations, podcasts, clinicians, dermatology reference sites and MorgellonsSurvey.org itself.
- Which definition of Morgellons did they use?
- Who was counted, where, and when?
- Did investigators count people who had it, people newly developing it, or the share of patients at one clinic?
- What comparison group received the same examination?
- Has the result been independently replicated?
- Do it is known, incidence or national average describe something the investigators actually measured?
The patient whose sore began three years ago deserves to be counted accurately. So does the patient whose first sore appeared this morning. Right now, nobody can say how many people belong to that second group in a given year.
How sources were selected
This is a narrative review by a patient advocate. On November 21, 2026, a Europe PMC search of titles and abstracts combined “Morgellons” or “unexplained dermopathy” with “prevalence,” “incidence,” “epidemiology,” or “cohort.” It returned 11 records. Following references from Fesler’s paper led to Mayne’s Australian study. Separate searches identified the U.S. Lyme claims and delusional infestation comparisons. I compared the original case definitions, tables and calculations, and traced the 6% figure through later papers, public commentary and the episode transcript. The linked sources document different things: clinical studies supply patient counts, while the other sources show how people described those counts. The search was selective. Claims about missing evidence apply to the sources reviewed here.
FAQ
References
- Pearson ML, Selby JV, Katz KA, Cantrell V, Braden CR, Parise ME, Paddock CD, Lewin-Smith MR, Kalasinsky VF, Goldstein FC, Hightower AW, Papier A, Lewis B, Motipara S, Eberhard ML, Unexplained Dermopathy Study Team. Clinical, epidemiologic, histopathologic and molecular features of an unexplained dermopathy. PLoS One. 2012;7(1):e29908. doi:10.1371/journal.pone.0029908 (Journal article)
- Fesler MC, Middelveen MJ, Stricker RB. Clinical evaluation of Morgellons disease in a cohort of North American patients. Dermatol Reports. 2018;10(1):7660. doi:10.4081/dr.2018.7660 (PDF)
- Murphree J. Same Name, Different Patients: Why Morgellons Studies Keep Contradicting Each Other. Morgellons Survey.
- Murphree J. Criteria for photographing Morgellons disease. RealMorgellons. December 2023.
- Middelveen MJ, Mayne PJ, Kahn DG, Stricker RB. Characterization and evolution of dermal filaments from patients with Morgellons disease. Clin Cosmet Investig Dermatol. 2013;6:1-21. doi:10.2147/CCID.S39017
- Naidoo A, Lepping P. Morgellons disease. DermNet. Reviewed 2024.
- Bailey CH, Andersen LK, Lowe GC, Pittelkow MR, Bostwick JM, Davis MD. A population-based study of the incidence of delusional infestation in Olmsted County, Minnesota, 1976-2010. Br J Dermatol. 2014;170(5):1130-1135. doi:10.1111/bjd.12848
- Mayne PJ. Clinical determinants of Lyme borreliosis, babesiosis, bartonellosis, anaplasmosis, and ehrlichiosis in an Australian cohort. Int J Gen Med. 2015;8:15-26. doi:10.2147/ijgm.s75825 (PDF)
- Girvan B (host), Fesler MC (guest). Understanding Morgellons with Melissa Fesler, Nurse Practitioner and Researcher. What the Morgs? October 15, 2026. Podcast, 38 minutes. (Episode transcript)
- Kugeler KJ, Schwartz AM, Delorey MJ, Mead PS, Hinckley AF. Estimating the Frequency of Lyme Disease Diagnoses, United States, 2010-2018. Emerg Infect Dis. 2021;27(2):616-619. doi:10.3201/eid2702.202731 (Journal text, PDF, figure on p. 617, Original figure)
- Middelveen MJ, Stricker RB. Morgellons disease: a filamentous borrelial dermatitis. Int J Gen Med. 2016;9:349-354. doi:10.2147/ijgm.s116608
- Charles E. Holman Morgellons Disease Foundation. New study highlights role of Lyme disease in bizarre skin disorder. May 1, 2018. Press release.
- Middelveen MJ, Sapi E, Burke J, Filush KR, Franco A, Fesler MC, Stricker RB. Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease. Healthcare (Basel). 2018;6(2):E33. doi:10.3390/healthcare6020033
- Middelveen MJ, Filush KR, Bandoski C, Kasliwala RS, Melillo A, Stricker RB, Sapi E. Mixed Borrelia burgdorferi and Helicobacter pylori Biofilms in Morgellons Disease Dermatological Specimens. Healthcare (Basel). 2019;7(2):E70. doi:10.3390/healthcare7020070
- For a rare disorder, is language complicating care? Undark. February 24, 2026.
- Mya Care. Morgellons disease: explaining the controversy, causes, risks, and more.
- Middelveen MJ, Bandoski C, Burke J, Sapi E, Filush KR, Wang Y, Franco A, Mayne PJ, Stricker RB. Exploring the association between Morgellons disease and Lyme disease: identification of Borrelia burgdorferi in Morgellons disease patients. BMC Dermatol. 2015;15(1):1. doi:10.1186/s12895-015-0023-0
- Hinckley AF, Connally NP, Meek JI, Johnson BJ, Kemperman MM, Feldman KA, White JL, Mead PS. Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis. 2014;59(5):676-681. doi:10.1093/cid/ciu397
- Schwartz AM, Kugeler KJ, Nelson CA, Marx GE, Hinckley AF. Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010-2018. Emerg Infect Dis. 2021;27(2):499-507. doi:10.3201/eid2702.202728
- Cocoros NM, Kluberg SA, Willis SJ, Forrow S, Gessner BD, Nutt CT, Cane A, Petrou N, Sury M, Rhee C, Jodar L, Mendelsohn A, Hoffman ER, Jin R, Aucott J, Pugh SJ, Stark JH. Validation of Claims-Based Algorithm for Lyme Disease, Massachusetts, USA. Emerg Infect Dis. 2023;29(9):1772-1779. doi:10.3201/eid2909.221931
- Kluberg SA, Cocoros NM, O'Neill J, Boyce TG, Sundaram ME, Schotthoefer A, Greenlee RT, Djibo DA, McMahill-Walraven CN, Aucott J, Moïsi JC, Jodar L, Willis SJ, Stark JH. Validation of Algorithms to Detect Acute and Disseminated Lyme Disease in U.S. Administrative Claims Data. Open Forum Infect Dis. 2025;12(4):ofaf109. doi:10.1093/ofid/ofaf109
- Centers for Disease Control and Prevention. Clinical testing and diagnosis for Lyme disease.
- Molins CR, Sexton C, Young JW, Ashton LV, Pappert R, Beard CB, Schriefer ME. Collection and characterization of samples for establishment of a serum repository for lyme disease diagnostic test development and evaluation. J Clin Microbiol. 2014;52(10):3755-3762. doi:10.1128/JCM.01409-14
- Naesens R, Vermeiren S, Van Schaeren J, Jeurissen A. False positive Lyme serology due to syphilis: report of 6 cases and review of the literature. Acta Clin Belg. 2011;66(1):58-59. doi:10.2143/acb.66.1.2062517
- Lawrenz MB, Hardham JM, Owens RT, Nowakowski J, Steere AC, Wormser GP, Norris SJ. Human antibody responses to VlsE antigenic variation protein of Borrelia burgdorferi. J Clin Microbiol. 1999;37(12):3997-4004. doi:10.1128/jcm.37.12.3997-4004.1999
- Coughlin Q, Ridge G. Invisible invaders: a decade of delusional infestation cases in Connecticut (2013-2023). J Med Entomol. 2026;63(4):tjag108. doi:10.1093/jme/tjag108
- Foster AA, Hylwa SA, Bury JE, Davis MD, Pittelkow MR, Bostwick JM. Delusional infestation: clinical presentation in 147 patients seen at Mayo Clinic. J Am Acad Dermatol. 2012;67(4):673.e1-10. doi:10.1016/j.jaad.2011.12.012
- Kohorst JJ, Bailey CH, Andersen LK, Pittelkow MR, Davis MDP. Prevalence of Delusional Infestation-A Population-Based Study. JAMA Dermatol. 2018;154(5):615-617. doi:10.1001/jamadermatol.2018.0004
- Patriquin G, LeBlanc J, Heinstein C, Roberts C, Lindsay R, Hatchette TF. Cross-reactivity between Lyme and syphilis screening assays: Lyme disease does not cause false-positive syphilis screens. Diagn Microbiol Infect Dis. 2016;84:184–186.
- Centers for Disease Control and Prevention. CDC Laboratory Recommendations for Syphilis Testing, United States, 2024. MMWR Recomm Rep. 2024;73(RR-1):1–32.
- Waykar V, Wourms K, Tang M, Joseph V. Delusional infestation: an interface with psychiatry. BJPsych Advances. 2021;27(5):343–348. doi:10.1192/bja.2020.69
- Middelveen MJ, Martinez RM, Fesler MC, Sapi E, Burke J, Shah JS, Nicolaus C, Stricker RB. Classification and Staging of Morgellons Disease: Lessons from Syphilis. Clin Cosmet Investig Dermatol. 2020;13:145–164. doi:10.2147/CCID.S239840 (Stage comparison, p. 158, Lesion comparison, p. 159, Test results, p. 148)
- Kugeler KJ, Earley A, Mead PS, Hinckley AF. Surveillance for Lyme Disease After Implementation of a Revised Case Definition — United States, 2022. MMWR Morb Mortal Wkly Rep. 2024;73:118–123.